Carcinoma, Non-Small-Cell Lung Concept

subject area of

• 15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer  Academic Article
• 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review  Academic Article
• In VitroSurvival of Nonsmall Cell Lung Cancer Cells Following Combined Treatment with Ionizing Radiation and Photofrin-mediated Photodynamic Therapy  Academic Article
• MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer  Academic Article
• A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer  Conference Paper
• A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer  Academic Article
• A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)  Academic Article
• A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer  Academic Article
• A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer  Academic Article
• A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium  Academic Article
• A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer  Academic Article
• A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer  Academic Article
• A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer  Academic Article
• A Time-Trend Economic Analysis of Cancer Drug Trials  Academic Article
• A biological staging model for operable non-small cell lung cancer  Academic Article
• A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer  Academic Article
• A mixed methods approach to understand variation in lung cancer practice and the role of guidelines  Academic Article
• A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thorax  Academic Article
• A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience  Academic Article
• ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis  Academic Article
• Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer  Academic Article
• Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update  Academic Article
• Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?  Academic Article
• Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future  Academic Article
• Alterations of immune response of non-small cell lung cancer with Azacytidine  Academic Article
• Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer  Academic Article
• Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer  Academic Article
• Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer.  Academic Article
• Angiogenesis and non-small cell lung cancer  Academic Article
• Antiangiogenic Therapies in Non-Small-Cell Lung Cancer  Academic Article
• Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data  Academic Article
• Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer  Academic Article
• Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study  Academic Article
• Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy  Academic Article
• Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer  Academic Article
• Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck  Academic Article
• Body composition in patients with non−small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis  Academic Article
• Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors  Academic Article
• Brain Metastases in Non–Small-Cell Lung Cancer  Academic Article
• Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC  Academic Article
• Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy  Academic Article
• Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens  Academic Article
• Canadian Consensus Recommendations on the Management of MET-Altered NSCLC  Academic Article
• Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer  Academic Article
• Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer  Academic Article
• Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer  Academic Article
• Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial  Academic Article
• Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer  Academic Article
• Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline  Academic Article
• Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study  Academic Article
• Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System  Academic Article
• Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis  Academic Article
• Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.  Academic Article
• Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?  Academic Article
• Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.  Academic Article
• Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts  Academic Article
• Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients  Academic Article
• Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.  Academic Article
• Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer  Academic Article
• Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer  Academic Article
• Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial  Academic Article
• Combined chemotherapy and radiation therapy for non-small-cell lung cancer.  Academic Article
• Commentary: Seek (the nodes) and you shall find (the nodes)  Academic Article
• Commentary: Wedge versus segmentectomy—It is best to err on the side of caution  Academic Article
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Academic Article
• Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study  Academic Article
• Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans  Academic Article
• Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model  Academic Article
• Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer  Academic Article
• Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non–Small-Cell Lung Cancer  Academic Article
• Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada  Academic Article
• Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer  Academic Article
• Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective  Academic Article
• Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer  Academic Article
• DEALE-ing with Lung Cancer and Heart Failure  Academic Article
• Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial  Academic Article
• Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer  Academic Article
• Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non–Small Cell Lung Cancer in Canada  Academic Article
• Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis  Academic Article
• Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?  Academic Article
• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study  Academic Article
• Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes  Academic Article
• Efficacy and safety of Kanglaite injection combined with first-line platinum-based chemotherapy in patients with advanced NSCLC: a systematic review and meta-analysis of 32 RCTs  Academic Article
• Endobronchial Ultrasound Staging of Operable Non-small Cell Lung Cancer  Academic Article
• Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline  Academic Article
• Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy  Academic Article
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome  Academic Article
• Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer  Academic Article
• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer  Academic Article
• First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review  Academic Article
• Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer  Academic Article
• Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter  Academic Article
• Herceptest: Her2 expression and gene amplification in non-small cell lung cancer  Academic Article
• High Risk for Thoracotomy but not Thoracoscopic Lobectomy  Academic Article
• How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized?  Academic Article
• Hypoxia-inducible factor-1? in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways  Academic Article
• Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses  Academic Article
• Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review  Academic Article
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer  Academic Article
• Impact of the COVID-19 pandemic on non–small-cell lung cancer pathologic stage and presentation  Academic Article
• In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer  Academic Article
• Interobserver Variation in the Computed Tomographic Evaluation of Mediastinal Lymph Node Size in Patients With Potentially Resectable Lung Cancer  Academic Article
• Is Positron Emission Tomography for the Management of Potentially Operable Non-Small Cell Lung Cancer an Efficient Use of Quebec Health Care Resources?  Academic Article
• Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary?  Academic Article
• Les progrès du scanner permettent-ils de dépister le cancer bronchique ?  Academic Article
• Lung cancer in pulmonary fibrosis: no room for nihilism!  Academic Article
• Lung cancer.  Academic Article
• Lung cancer.  Academic Article
• Lung cancer.  Academic Article
• Lung cancer.  Academic Article
• Lung cancer.  Academic Article
• Management of unresected stage III non-small cell lung cancer: a systematic review.  Academic Article
• Matrix Metalloproteinase-19 Promotes Metastatic Behavior In Vitro and Is Associated with Increased Mortality in Non–Small Cell Lung Cancer  Academic Article
• Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.  Academic Article
• Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer  Academic Article
• Metabolic imaging in non-small-cell lung cancer radiotherapy  Academic Article
• Metformin for chemo-radio-sensitization of NSCLC  Academic Article
• Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer  Academic Article
• Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK  Academic Article
• Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology  Academic Article
• MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function  Academic Article
• Minimally invasive thoracic surgery for early stage non-small cell lung cancer  Academic Article
• Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial  Academic Article
• Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions  Academic Article
• N2 is not N2 is not N2  Academic Article
• Near-infrared mapping with indocyanine green is associated with an increase in oncological margin length in minimally invasive segmentectomy  Academic Article
• Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!  Academic Article
• Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer  Academic Article
• Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC  Academic Article
• Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer  Academic Article
• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study  Academic Article
• Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy  Academic Article
• Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval  Academic Article
• Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer  Academic Article
• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC  Academic Article
• PET–CT imaging in non-small-cell lung cancer  Academic Article
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial  Academic Article
• Pharmacoeconomics of Systemic Therapies for Lung Cancer  Academic Article
• Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations  Academic Article
• Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer  Academic Article
• Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors  Academic Article
• Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients  Academic Article
• Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer  Academic Article
• Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group  Academic Article
• Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer  Academic Article
• Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25  Academic Article
• Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer  Academic Article
• Phase II Trial of 13-cis-Retinoic Acid Plus Interferon   in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group  Academic Article
• Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma  Academic Article
• Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition  Academic Article
• Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors  Academic Article
• Positron Emission Tomography Plus Computed Tomography for Staging Early Lung Cancer  Academic Article
• Positron Emission Tomography in Staging Early Lung Cancer  Academic Article
• Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial  Academic Article
• Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small-Cell Lung Cancer: A Systematic Review  Academic Article
• Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline  Academic Article
• Practitioner feedback on lung cancer practice guidelines in Ontario.  Academic Article
• Predicting 2-Year Survival for Radiation Regimens in Advanced Non-small Cell Lung Cancer  Academic Article
• Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non–small-cell lung cancer: Which is better?  Academic Article
• Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non–Small-Cell Lung Cancer  Academic Article
• Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer  Academic Article
• Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value  Academic Article
• RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer  Academic Article
• RNAi screen identifies essential regulators of human brain metastasis-initiating cells  Academic Article
• Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non–Small-cell Lung Cancer: A Systematic Review  Academic Article
• Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29  Academic Article
• Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer  Conference Paper
• Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer  Conference Paper
• Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer  Academic Article
• Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18  Academic Article
• Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer  Academic Article
• Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)  Academic Article
• Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study  Academic Article
• Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia  Academic Article
• Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597  Academic Article
• Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung  Academic Article
• Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth  Academic Article
• Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort  Academic Article
• Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis  Academic Article
• Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario  Academic Article
• Respiratory Failure Following Vinorelbine Tartrate Infusion in a Patient With Non-small Cell Lung Cancer  Academic Article
• Response to Screening for Brain Metastases in Resectable Non–Small Cell Lung Cancer  Academic Article
• Robotic Versus Video-Assisted Thoracoscopic Lung Resection During Early Program Development  Academic Article
• Robotic resection of Stage III lung cancer: an international retrospective study†  Academic Article
• Robotic vs Thoracoscopic Anatomic Lung Resection in Obese Patients: A Propensity-Adjusted Analysis  Academic Article
• Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Academic Article
• Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial  Academic Article
• SUNSET: Stereotactic Radiation for Ultracentral Non–Small-Cell Lung Cancer—A Safety and Efficacy Trial  Academic Article
• Sclerosing angiomatoid nodular transformation of the spleen: Case report  Academic Article
• Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations  Academic Article
• Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  Academic Article
• Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219  Academic Article
• Skeletal Muscle Depletion Is Associated with Reduced Plasma (n-3) Fatty Acids in Non-Small Cell Lung Cancer Patients  Academic Article
• Stage III Non–Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment  Academic Article
• Stuck between a rock and a hard place: ILD + NSCLC = LIM  Academic Article
• Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer  Academic Article
• Surgeons’ assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer  Academic Article
• Surgery after Chemoradiotherapy in Patients with Stage III (n2 or N3, Excluding T4) Non-Small-Cell Lung Cancer: A Systematic Review  Academic Article
• Survival effects of time to surgery for Stage I lung cancer: A population-based study  Academic Article
• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update  Academic Article
• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update  Academic Article
• TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer  Academic Article
• Takotsubo Cardiomyopathy Secondary in Part to Cancer-Related Pain Crisis: A Case Report  Academic Article
• Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer  Academic Article
• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?  Academic Article
• Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline  Academic Article
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial  Academic Article
• Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study  Academic Article
• The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Academic Article
• The burden of death following discharge after lobectomy  Academic Article
• The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer.  Academic Article
• The effect of surgeon volume on procedure selection in non–small cell lung cancer surgeries  Academic Article
• The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer  Academic Article
• The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer  Academic Article
• The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update  Academic Article
• Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.  Academic Article
• Towards a biological staging model for operable non-small cell lung cancer  Academic Article
• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers  Academic Article
• Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing  Academic Article
• Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24  Academic Article
• Trends in Survival Based on Treatment Modality in Non-Small Cell Lung Cancer Patients: A Population-Based Study  Academic Article
• Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer  Academic Article
• Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables  Academic Article
• Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada  Academic Article
• Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?  Academic Article
• Unerwünschte (kardio-)vaskuläre Wirkungen von Vinorelbin beim nichtkleinzelligen Bronchialkarzinom1  Academic Article
• Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.  Academic Article
• Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial  Academic Article
• Uptake and survival effects of minimally invasive surgery for lung cancer: A population-based study  Academic Article
• Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.  Academic Article
• Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?  Academic Article
• Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer  Academic Article
• Wait times in the management of non–small cell lung carcinoma before, during and after regionalization of lung cancer care: a high-resolution analysis  Academic Article
• Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.  Academic Article
• YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer  Academic Article
• Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity  Academic Article
• [A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy].  Academic Article
• p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness  Academic Article
• “Incomplete Resection” in Non–Small Cell Lung Cancer: Need for a New Definition  Academic Article